Antibiotic consumption of inpatients with inflammatory bowel disease during 2015-2024 and future prediction: Evidence from a general hospital

doi:10.3748/wjg.v32.i4.115040

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 4

This Article

(53)

(41)

(0)

(1)

(796)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jan 28, 2026; 32(4): 115040
Published online Jan 28, 2026. doi: 10.3748/wjg.v32.i4.115040

Full Size Figure Download Figure

Figure 3 Causes of antibiotic treatments in ulcerative colitis and Crohn’s disease. A: Ulcerative colitis; B: Crohn’s disease. UC: Ulcerative colitis; CD: Crohn’s disease.

Citation: Zeng W, Zhang WK, Xu D, He K, Huang YP, Liu YX, Yang HF. Antibiotic consumption of inpatients with inflammatory bowel disease during 2015-2024 and future prediction: Evidence from a general hospital. World J Gastroenterol 2026; 32(4): 115040
URL: https://www.wjgnet.com/1007-9327/full/v32/i4/115040.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i4.115040

Zeng W, Zhang WK, Xu D, He K, Huang YP, Liu YX, Yang HF. Antibiotic consumption of inpatients with inflammatory bowel disease during 2015-2024 and future prediction: Evidence from a general hospital. World J Gastroenterol 2026; 32(4): 115040 [PMID: 41640873 DOI: 10.3748/wjg.v32.i4.115040]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.